Total Payments
$335,831
2024 Payments
$149.18
Companies
34
Transactions
381
Medicare Patients
496
Medicare Billing
$124,452
Payment Breakdown by Category
Other$203,416 (60.6%)
Consulting$82,222 (24.5%)
Travel$37,230 (11.1%)
Food & Beverage$12,779 (3.8%)
Research$184.22 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $203,416 | 55 | 60.6% |
| Consulting Fee | $82,222 | 36 | 24.5% |
| Travel and Lodging | $37,230 | 121 | 11.1% |
| Food and Beverage | $12,779 | 167 | 3.8% |
| Unspecified | $184.22 | 2 | 0.1% |
Payments by Type
General
$335,647
379 transactions
Research
$184.22
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $77,033 | 59 | $0 (2023) |
| Seagen Inc. | $68,587 | 54 | $0 (2023) |
| Helsinn Therapeutics (U.S.), Inc. | $63,432 | 49 | $0 (2022) |
| TAIHO ONCOLOGY, INC. | $23,739 | 35 | $0 (2023) |
| Daiichi Sankyo Inc. | $23,192 | 25 | $0 (2022) |
| Eisai Inc. | $19,089 | 27 | $0 (2023) |
| Exelixis Inc. | $13,395 | 36 | $0 (2023) |
| PFIZER INC. | $10,100 | 4 | $0 (2021) |
| Incyte Corporation | $7,586 | 14 | $0 (2021) |
| Astellas Pharma US Inc | $7,573 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $149.18 | 1 | Astellas Pharma US Inc ($149.18) |
| 2023 | $129,931 | 116 | AstraZeneca Pharmaceuticals LP ($64,045) |
| 2022 | $85,927 | 95 | Helsinn Therapeutics (U.S.), Inc. ($44,397) |
| 2021 | $57,961 | 41 | Helsinn Therapeutics (U.S.), Inc. ($19,035) |
| 2020 | $21,134 | 25 | AstraZeneca Pharmaceuticals LP ($9,245) |
| 2019 | $38,895 | 90 | Taiho Oncology, Inc. ($9,951) |
| 2018 | $1,619 | 7 | Incyte Corporation ($1,139) |
| 2017 | $214.32 | 6 | Lexicon Pharmaceuticals, Inc. ($126.71) |
All Payment Transactions
381 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/19/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $149.18 | General |
| 07/18/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Consulting Fee | Cash or cash equivalent | $1,980.00 | General |
| Category: Oncology | ||||||
| 07/18/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Travel and Lodging | Cash or cash equivalent | $75.00 | General |
| Category: Oncology | ||||||
| 06/30/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $135.17 | General |
| 06/14/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,100.00 | General |
| Category: Oncology | ||||||
| 06/13/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Oncology | ||||||
| 06/12/2023 | Seagen Inc. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,400.00 | General |
| Category: Oncology | ||||||
| 06/12/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $785.97 | General |
| Category: Oncology | ||||||
| 06/12/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $399.99 | General |
| Category: Oncology | ||||||
| 06/12/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $244.80 | General |
| Category: Oncology | ||||||
| 06/12/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | Cash or cash equivalent | $41.12 | General |
| Category: Oncology | ||||||
| 06/12/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Oncology | ||||||
| 06/09/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Oncology | ||||||
| 06/09/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Oncology | ||||||
| 06/09/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Oncology | ||||||
| 06/07/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Oncology | ||||||
| 06/07/2023 | Seagen Inc. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: Oncology | ||||||
| 06/07/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $121.42 | General |
| Category: Oncology | ||||||
| 06/07/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $65.00 | General |
| Category: Oncology | ||||||
| 06/06/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $1,831.60 | General |
| Category: Oncology | ||||||
| 06/06/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $250.27 | General |
| Category: Oncology | ||||||
| 06/06/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $41.62 | General |
| Category: Oncology | ||||||
| 06/06/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $34.24 | General |
| Category: Oncology | ||||||
| 06/06/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 06/01/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $303.68 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | Seattle Genetics, Inc. | $119.22 | 1 |
| A Phase I Study of BMS-986299 as Monotherapy and in Combination with Nivolumab and Ipilimumab in Participants with Advanced Solid Cancers | E.R. Squibb & Sons, L.L.C. | $65.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 47 | 119 | $83,461 | $14,685 |
| 2022 | 4 | 141 | 413 | $309,663 | $59,023 |
| 2021 | 4 | 118 | 194 | $121,301 | $25,824 |
| 2020 | 5 | 190 | 287 | $117,180 | $24,920 |
Total Patients
496
Total Services
1,013
Medicare Billing
$124,452
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 84 | $61,306 | $10,808 | 17.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 35 | $22,155 | $3,877 | 17.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 235 | $187,101 | $35,382 | 18.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 41 | 106 | $67,098 | $12,730 | 19.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $15,584 | $3,107 | 19.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 12 | 26 | $14,950 | $2,938 | 19.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $14,346 | $2,835 | 19.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $10,584 | $2,031 | 19.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 19 | 44 | $34,706 | $7,015 | 20.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 24 | 39 | $22,977 | $4,984 | 21.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 21 | 46 | $16,594 | $3,832 | 23.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 24 | $11,835 | $2,763 | 23.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $12,059 | $2,583 | 21.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $12,546 | $2,565 | 20.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 12 | $10,584 | $2,082 | 19.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 29 | 82 | $26,568 | $7,217 | 27.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 57 | 88 | $31,816 | $5,723 | 18.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 44 | 57 | $26,870 | $4,877 | 18.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 34 | 34 | $22,874 | $4,659 | 20.4% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 26 | 26 | $9,052 | $2,444 | 27.0% |
About Dr. May Cho, M.D
Dr. May Cho, M.D is a Internal Medicine healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2011. The National Provider Identifier (NPI) number assigned to this provider is 1619263514.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. May Cho, M.D has received a total of $335,831 in payments from pharmaceutical and medical device companies, with $149.18 received in 2024. These payments were reported across 381 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($203,416).
As a Medicare-enrolled provider, Cho has provided services to 496 Medicare beneficiaries, totaling 1,013 services with total Medicare billing of $124,452. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Medical Oncology
- Location Orange, CA
- Active Since 06/20/2011
- Last Updated 04/17/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1619263514
Products in Payments
- IMFINZI (Biological) $67,685
- TRUSELTIQ (Drug) $63,432
- TUKYSA (Drug) $53,147
- Lonsurf (Drug) $17,596
- Lenvima (Drug) $16,913
- ENHERTU (Drug) $13,004
- TIVDAK (Biological) $12,670
- BRAFTOVI (Drug) $10,830
- Cabometyx (Drug) $10,370
- Enhertu (Drug) $10,112
- LONSURF (Drug) $6,144
- OPDIVO (Biological) $4,417
- TECENTRIQ (Biological) $2,974
- ONIVYDE (Drug) $2,880
- CABOMETYX (Drug) $2,797
- Vectibix (Biological) $2,314
- Stivarga (Drug) $1,804
- Intera 3000 Implantable Pump (Device) $267.29
- IMFINZI (Drug) $235.56
- SIR-Spheres Microspheres (Device) $156.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Orange
Dr. Elizabeth Brem, Md, MD
Internal Medicine — Payments: $285,872
Internal Medicine $285,872
Dr. Ritesh Parajuli, Md, MD
Internal Medicine — Payments: $180,846
Internal Medicine $180,846
Beth Valashinas, Do, DO
Internal Medicine — Payments: $96,719
Internal Medicine $96,719
Dr. Jennifer Valerin, M.d, M.D
Internal Medicine — Payments: $83,603
Internal Medicine $83,603
Dr. Teferi Mitiku, M.d, M.D
Internal Medicine — Payments: $69,169
Internal Medicine $69,169
Sendhil Krishnan, Md, Facc, MD, FACC
Internal Medicine — Payments: $40,364
Internal Medicine $40,364